Category Archives: Uncategorized

How Egypt came to treat over 1 million patients with Hepatitis C

Posted in Uncategorized | Leave a comment

Australian duo find global consumers for Indian generic drugs

By Divya Rajagopal, The Economic Times | May 23, 2017 MUMBAI: Remember Ron the rodeo cowboy from the Oscar-winning film Dallas Buyers Club? The biopic portrayed the story of Ron Woodroof, an AIDS patient in the mid-1980s who signed up … Continue reading

Posted in Generics, Hepatitis C, Sofosbuvir, Uncategorized | Leave a comment

Better life through medicine—let’s leave no one behind

Source: http://www.thelancet.com The Lancet Commission on Essential Medicines Policies  rightfully addresses the need to guarantee access to essential medicines for all. However, we cannot achieve any real progress without acknowledging that the current patent-based business model and the way we … Continue reading

Posted in Delinkage, R&D, R&D, Sofosbuvir, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

Pharmaceuticals & Patents, a talk by Justice Prabha Sridevan

  I am grateful to the Dr. N.S. Gopalakrishnan for inviting me to inaugurate this workshop, the theme being “Pharmaceuticals and patents.” This is a very important one today when there is a claim for a strong patent regime. But I must … Continue reading

Posted in Patent, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Roche vs Indian Pharma: The battle for a cheaper cancer drug

By Divya Rajagopal, The Economic Times|May 14, 2017 Let’s hark back to the Nineties. The HIV-AIDS epidemic was spreading across Africa, leaving thousands dead, in spite of the existence of anti-retroviral drugs (ARVs). The cost of the treatment, around $10,000, … Continue reading

Posted in Biologics/Biosimilars, Campaign for Affordable Trastuzumab, Cancer, Uncategorized | Leave a comment

Why RCEP is the problem, not the solution

Source: inquirer.net | May 17, 2017 On May 2-12, the 16 member-countries of the Regional Comprehensive Economic Partnership (RCEP) met in Manila for their 18th round of negotiations to craft a multilateral trade deal that would affect half of the world’s … Continue reading

Posted in Investor state dispute, IP Rights, ISDS, Regional Comprehensive Economic Partnership, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Intellectual property, affordable medicine, and universal health care

By Dr. Maria Guevara, Business world online| May 05, 2017 MANILA IS SET to host the 18th round of the multilateral trade deal — the Regional Comprehensive Economic Partnership (RCEP) that encompasses 50% of the global population.  With the Philippines … Continue reading

Posted in IPR, Patent, Patents, Regional Comprehensive Economic Partnership, TPP, TRIPS, Uncategorized | Leave a comment